Do Not Routinely Discontinue Spironolactone with eGFR <30 mL/min/1.73 m²
You should NOT automatically stop spironolactone when eGFR consistently falls below 30 mL/min/1.73 m², as these medications remain nephroprotective even in advanced CKD. However, this requires careful clinical judgment based on the specific indication, potassium levels, and close monitoring.
Clinical Decision Framework
For Heart Failure with Reduced Ejection Fraction (HFrEF)
The 2022 AHA/ACC/HFSA guidelines explicitly state that mineralocorticoid receptor antagonists (MRAs) are recommended when eGFR >30 mL/min/1.73 m² and serum potassium <5.0 mEq/L 1. This represents a Class I, Level A recommendation for patients with NYHA class II-IV symptoms.
However, the KDOQI guidelines provide critical nuance: they explicitly state "Do not routinely discontinue in people with GFR <30 ml/min/1.73 m² as they remain nephroprotective" 2. This creates an important distinction:
- Do not initiate spironolactone if eGFR is already <30 mL/min/1.73 m²
- Do not routinely discontinue if eGFR falls below 30 while on therapy
For Diabetic Kidney Disease
The 2022 KDIGO diabetes guideline recommends nonsteroidal MRAs for patients with eGFR ≥25 mL/min/1.73 m² 3. While this specifically addresses newer agents like finerenone, the principle of continued nephroprotection applies to spironolactone as well.
Monitoring Requirements When Continuing Below eGFR 30
If you continue spironolactone with eGFR <30 mL/min/1.73 m²:
- Check potassium and renal function within 3 days and at 1 week after any dose adjustment 4
- Monthly monitoring for first 3 months, then every 3 months 1, 5
- More frequent monitoring if clinical instability, concurrent illness, or other medications affecting potassium
Mandatory Discontinuation Criteria
Stop spironolactone immediately if:
- Potassium >6.0 mEq/L 5
- Creatinine >310 μmol/L (3.5 mg/dL) or eGFR <20 mL/min/1.73 m² 5
- Symptomatic hyperkalemia regardless of level
Reduce dose by 50% if:
Evidence Supporting Continuation
Real-world data demonstrates that stopping spironolactone after hyperkalemia episodes is associated with higher risk of death or cardiovascular events despite reducing recurrent hyperkalemia risk 7. A propensity-matched study showed improved 2-year survival in heart failure patients with renal dysfunction (eGFR <60) treated with spironolactone, despite worsening renal function and increased potassium 8.
Common Pitfalls to Avoid
Do not automatically discontinue during:
- Intercurrent illness (temporarily suspend instead) 2
- Planned procedures requiring bowel preparation 2
- Episodes of diarrhea or dehydration (temporarily hold) 4, 5
Critical medication interactions requiring dose reduction or discontinuation:
- Triple therapy with ACEi + ARB + MRA is NOT recommended 4, 5
- Avoid potassium supplements when initiating MRA 4
- Avoid NSAIDs, trimethoprim, and "low-salt" potassium-containing substitutes 5
Practical Dosing with eGFR 30-50 mL/min/1.73 m²
For patients with eGFR between 30-50 mL/min/1.73 m²:
- Initiate at 25 mg every other day rather than daily 1, 6
- Consider starting at 12.5 mg daily as alternative 4
- Maximum dose typically 25 mg daily in this range
Context-Specific Considerations
The 2025 European Heart Failure Association consensus acknowledges that in acute decompensated heart failure with low blood pressure, MRAs should be reduced or stopped if eGFR <30 mL/min/1.73 m² 7. This represents a different clinical scenario than stable chronic heart failure.
The key distinction: In stable outpatients with chronic heart failure, the nephroprotective benefits may outweigh risks even below eGFR 30, whereas in acute decompensation, the immediate safety concerns take precedence.